For our first quarter 2026 earnings call, today, I'll review key takeaways and provide an update on our platform programs. Following my review of recent developments at INmune Bio, I will pass the ...
Hit identification and hit validation represent distinct but connected stages of early drug discovery. This article examines ...
State and local AI laws governing hiring and selection procedures are already in effect with more on the way. Employers can take ...
Mental health clinicians have started asking clients how they use generative artificial intelligence chatbots to support ...
Greetings, and welcome to the INmune Bio's 2026 First Quarter Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this ...
A full Livebeam review of the verification process — how moderation works, what to expect at each step, and how customer ...
CFO Francisco noted, "Our 2026 total revenue guidance now reflects the expectation that we see more measured improvement in clinician confusion and the overall operating environment as we move through ...
Discover how OpenAI Symphony shifts AI coding from session-based to task-oriented workflows to automate ticketing and reduce ...
UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.48244. Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Q1 2026 Results ...
We've got Corrie Hassan, the current CEO of Spenda over today; and Karim Razak, the Executive Chairman, joining us to give us an update on the March or Q3 quarterly. I'm going to hand over to Corrie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results